FDA expands approval of BioCryst's rare disease drug for use in young children

Core Insights - The U.S. Food and Drug Administration (FDA) has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 and older [1] Company Summary - BioCryst Pharmaceuticals has received FDA approval for a new oral pellet formulation of its drug, which is aimed at preventing hereditary angioedema attacks in pediatric patients [1]